Skip to main navigation menu Skip to main content Skip to site footer
×
Español (España) | English
Editorial
Home
Indexing
Review

PCSK9 inhibition: a new alternative to reduce cholesterol and prevent atherosclerotic cardiovascular disease

By
Gabriela Alexandra Solano Peña ,
Gabriela Alexandra Solano Peña

Solca Núcleo Tungurahua, Ecuador.

Search this author on:

PubMed | Google Scholar
Gabriela Fernanda Acurio Armas ,
Gabriela Fernanda Acurio Armas

Médico Investigador Independiente, Ecuador.

Search this author on:

PubMed | Google Scholar
Gabriela Alejandra Díaz Teran ,
Gabriela Alejandra Díaz Teran

Hospital General de Latacunga, Ecuador.

Search this author on:

PubMed | Google Scholar
Susana Patricia Palacios Serrano ,
Susana Patricia Palacios Serrano

Hospital Regional Docente Ambato, Ecuador.

Search this author on:

PubMed | Google Scholar
Andrea Carolina Cobo Reyes ,
Andrea Carolina Cobo Reyes

Hospital Básico Salcedo, Ecuador.

Search this author on:

PubMed | Google Scholar
Daniel Albino Pullas Taboada ,
Daniel Albino Pullas Taboada

Médico Investigador Independiente, Ecuador.

Search this author on:

PubMed | Google Scholar
Gissel Katherine Carvajal Chango ,
Gissel Katherine Carvajal Chango

Hospital Regional Docente Ambato, Ecuador.

Search this author on:

PubMed | Google Scholar

Abstract

Introduction: Atherosclerotic cardiovascular disease is the leading cause of mortality and morbidity worldwide. One of the key factors in its development is elevated LDL cholesterol. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a molecule that regulates LDL cholesterol levels.
Objective: The purpose of this review is to provide a comprehensive analysis of the evidence surrounding PCSK9 inhibition as an effective therapy for reducing cholesterol and preventing atherosclerotic cardiovascular disease.
Methodology: A comprehensive literature review was conducted using medical databases, including PubMed, Embase, and Cochrane Library. Search terms included "PCSK9," "PCSK9 inhibitors," "cholesterol," "LDL," and "atherosclerotic cardiovascular disease."
Results: Evidence suggests that PCSK9 inhibitors are effective in reducing LDL cholesterol levels in patients with hypercholesterolemia. Several clinical trials have demonstrated that these drugs can reduce LDL cholesterol by up to 60% compared to placebo. Additionally, PCSK9 inhibitors appear to have a favorable safety profile and are well-tolerated by most patients. Several studies have also shown that PCSK9 inhibitors can reduce the risk of cardiovascular events in patients with pre-existing atherosclerotic disease.
Conclusion: PCSK9 inhibitors represent a promising therapeutic strategy for LDL cholesterol control and prevention of atherosclerotic cardiovascular disease. Future studies should focus on determining the long-term effect of these drugs on cardiovascular morbidity and mortality and exploring ways to improve access and affordability to these therapies.

How to Cite

1.
Solano Peña GA, Acurio Armas GF, Díaz Teran GA, Palacios Serrano SP, Cobo Reyes AC, Pullas Taboada DA, Carvajal Chango GK. PCSK9 inhibition: a new alternative to reduce cholesterol and prevent atherosclerotic cardiovascular disease. Salud, Ciencia y Tecnología [Internet]. 2023 Nov. 13 [cited 2024 Jun. 16];3:587. Available from: https://revista.saludcyt.ar/ojs/index.php/sct/article/view/587

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.